List of Excipients in Branded Drug ADRENALIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Henry Schein Inc	ADRENALIN	epineprine	0404-9810	EDETATE DISODIUM
Henry Schein Inc	ADRENALIN	epineprine	0404-9810	HYDROCHLORIC ACID
Henry Schein Inc	ADRENALIN	epineprine	0404-9810	SODIUM CHLORIDE
Henry Schein Inc	ADRENALIN	epineprine	0404-9810	SODIUM HYDROXIDE
Henry Schein Inc	ADRENALIN	epineprine	0404-9810	SODIUM METABISULFITE
Henry Schein Inc	ADRENALIN	epineprine	0404-9810	TARTARIC ACID

Adrenalin Excipient Strategy and Commercial Opportunities for Epinephrine Products

Last updated: August 18, 2026

Adrenalin is a branded epinephrine injection product used for severe allergic reactions, cardiac arrest, and other emergency indications. The active ingredient is chemically unstable, oxidation-sensitive, and difficult to deliver consistently through patient-operated devices. The strongest commercial opportunities are therefore in stability-enhancing excipients, nasal absorption systems, ready-to-use presentations, device compatibility, and differentiated delivery platforms rather than in the epinephrine molecule itself.

The principal excipient constraints are oxidation, pH control, sulfite sensitivity, tonicity, container compatibility, sterility, and rapid systemic absorption. Injectable epinephrine products generally rely on simple formulations, while newer nasal products use absorption-enhancing excipients to compete with autoinjectors.

What excipients are used in Adrenalin and epinephrine products?

Adrenalin injection formulations typically contain sodium chloride, sodium metabisulfite, hydrochloric acid for pH adjustment, and water for injection. The formulation is designed to maintain epinephrine stability in an acidic aqueous environment and provide an injectable isotonic solution.[1]

Product or product type	Active ingredient	Representative excipients	Primary formulation purpose
Adrenalin injection	Epinephrine	Sodium chloride, sodium metabisulfite, hydrochloric acid, water for injection	Tonicity, antioxidant protection, pH adjustment
Epinephrine autoinjectors	Epinephrine	Sodium chloride, sodium metabisulfite, hydrochloric acid, water	Stability and device-compatible injection
Generic epinephrine injection	Epinephrine	Usually comparable to reference formulation	ANDA-based pharmaceutical equivalence
Neffy nasal spray	Epinephrine	Dodecylmaltoside, phosphate buffer system, sodium chloride, disodium edetate and other formulation excipients identified in labeling	Nasal absorption enhancement, pH control, chelation and tonicity
Nebulized epinephrine products	Epinephrine	Product-specific; may be limited to aqueous vehicle and pH or tonicity agents	Pulmonary delivery and aerosol performance

The exact excipient composition varies by strength, route, dosage form, manufacturer, and regulatory filing. A product labeled “Adrenalin” should not be treated as interchangeable with every epinephrine product because route, concentration, preservative status, device, and intended use can differ.

Why is sodium metabisulfite used in epinephrine?

Sodium metabisulfite is used as an antioxidant. Epinephrine can degrade through oxidation, producing discoloration and loss of potency. Sulfite reduces oxidative degradation but creates a labeling and commercial issue because some patients report sulfite sensitivity.

The presence of sulfite does not eliminate the clinical use of epinephrine in anaphylaxis. FDA labeling states that the benefits of epinephrine may outweigh the risks associated with sulfite exposure in emergency treatment.[1] A commercially differentiated product could seek a sulfite-free formulation, but it would need to demonstrate equivalent stability, potency, impurity control, and shelf life.

What excipients improve epinephrine nasal absorption?

Nasal epinephrine products require an absorption strategy because epinephrine has limited and variable systemic uptake through the nasal mucosa. Neffy uses dodecylmaltoside as a nasal absorption enhancer. The excipient alters the local membrane environment and supports delivery across the nasal epithelium.[2]

Potential development candidates include surfactants, mucoadhesive polymers, cyclodextrins, chelating agents, and buffer systems. Each candidate creates a separate safety and regulatory burden. Nasal irritation, ciliotoxicity, variability caused by congestion, and repeated-use tolerability are key development risks.

How does excipient selection affect epinephrine stability?

Epinephrine stability depends on oxygen exposure, light, pH, temperature, metal ions, packaging, and manufacturing conditions. The most important formulation variables are:

1. Acidic pH control.
2. Antioxidant selection.
3. Metal-ion control.
4. Oxygen management.
5. Container closure protection.
6. Light protection.
7. Sterile manufacturing controls.

pH and oxidation control

Epinephrine is generally stabilized in an acidic solution. Hydrochloric acid or a phosphate-based buffer may be used to establish the target pH. A lower pH can reduce oxidation but may affect injection tolerability, nasal tolerability, device materials, and chemical degradation pathways.

A formulation program should evaluate:

• Epinephrine assay and related substances.
• Adrenochrome and other oxidation products.
• Color change.
• pH drift.
• Particulate formation.
• Container closure integrity.
• Stability after device actuation.
• Stability under temperature excursions.

Chelators and trace metals

Trace metals can catalyze oxidation. Disodium edetate may reduce metal-mediated degradation and can support a lower-antioxidant strategy. The commercial value of a chelator is greatest when it enables a lower sulfite concentration, longer shelf life, or reduced sensitivity to manufacturing variability.

Chelators also create compatibility and regulatory questions. Their concentration must be justified against local tolerability, route-specific exposure, and the risk of altering container materials or device components.

Packaging is part of the excipient strategy

For epinephrine, formulation and packaging cannot be separated. Glass, elastomer closures, syringe barrels, autoinjector cartridges, nasal spray pumps, and protective overwraps can affect oxygen ingress, adsorption, extractables, leachables, and delivered dose.

Commercially relevant packaging improvements include:

• Low-oxygen headspace systems.
• Light-protective primary containers.
• Low-permeability elastomers.
• Siliconization controls.
• Pre-filled syringes with validated lubricant levels.
• Cartridge systems compatible with autoinjector force requirements.
• Nasal devices with reproducible plume geometry.
• Unit-dose packaging that reduces repeated opening and contamination.

What commercial opportunities exist for Adrenalin excipient innovation?

The largest opportunities are in patient convenience, shelf-life extension, sulfite reduction, nasal delivery, and hospital workflow.

1. Sulfite-free or low-sulfite epinephrine

A sulfite-free product could address patient and prescriber concerns about sulfite exposure. The development challenge is substantial because the formulation must maintain potency through the labeled shelf life without relying on the conventional antioxidant system.

Potential approaches include:

• Oxygen-reduced filling.
• Nitrogen purging.
• Chelator-assisted stabilization.
• Alternative antioxidants.
• Improved container closure systems.
• Light-resistant packaging.
• Lower-permeability devices.
• Freeze-dried or dual-chamber presentations.

A sulfite-free product would likely require a full stability package and could obtain protection through formulation claims, manufacturing claims, packaging claims, or a 505(b)(2) regulatory pathway if it relies partly on published or reference-product data.

2. Longer shelf life

Epinephrine products are often replaced because of expiration dates, discoloration concerns, or storage uncertainty. A longer shelf life could reduce waste for households, schools, emergency responders, hospitals, and public-access programs.

The value proposition is strongest where institutions maintain large emergency inventories. A six-month or one-year extension can produce measurable procurement savings and reduce replacement frequency.

The commercial evidence must include real-time and accelerated stability, temperature excursions, photostability, in-use stability, and device-function data. A formulation patent covering a stabilizer ratio or oxygen-control process may provide more practical value than a broad excipient claim that is difficult to enforce.

3. Nasal epinephrine

Nasal epinephrine is the most important route-of-administration opportunity. The FDA approved neffy in 2024 for emergency treatment of allergic reactions, including anaphylaxis, in adults and children weighing at least 30 kilograms.[2]

Nasal delivery can eliminate the needle, reduce training requirements, and improve acceptance among patients who do not carry or cannot correctly use an autoinjector. Its commercial performance depends on:

• Dose reproducibility.
• Absorption during nasal congestion.
• Performance after improper handling.
• Nasal irritation.
• Storage stability.
• Device usability.
• Competitive pricing against two-pack autoinjectors.

The key excipient opportunity is not simply identifying a new surfactant. It is developing an absorption-enhancer system with a favorable balance of bioavailability, local tolerability, repeated-use safety, and manufacturing robustness.

4. Prefilled syringes and hospital-ready presentations

Hospitals and emergency medical services can benefit from prefilled syringes that reduce preparation time and dosing errors. Excipient innovation may support:

• Longer in-device stability.
• Reduced adsorption to syringe components.
• Improved visibility of discoloration.
• Compatibility with automated medication systems.
• Reduced dead volume.
• Ready-to-administer concentrations.

The regulatory pathway may be more straightforward than for a new route, but the sponsor must demonstrate dose accuracy, sterility, container closure integrity, and compatibility with the intended clinical workflow.

5. Pediatric and weight-based delivery

Current emergency epinephrine products create dosing and handling challenges for children. Opportunities include:

• Lower-dose autoinjectors.
• Adjustable-dose devices.
• Pediatric nasal presentations.
• Unit-dose presentations with simplified labeling.
• Products optimized for smaller nasal cavities or lower administration force.

An excipient change alone may not create a pediatric product. The commercial opportunity generally requires coordination among formulation, device engineering, human factors, and dose selection.

How does Adrenalin compare with competing epinephrine delivery systems?

Attribute	Standard injection	Autoinjector	Nasal spray	Nebulized delivery
Primary user	Clinician or trained responder	Patient, caregiver or responder	Patient, caregiver or responder	Clinician or supervised user
Needle-free	No	No	Yes	Yes
Excipient complexity	Low to moderate	Low to moderate	Moderate to high	Low to moderate
Main formulation challenge	Sterility and stability	Stability-device compatibility	Absorption and nasal tolerability	Aerosol performance
Main commercial barrier	Administration expertise	Price and device usability	Clinical adoption and route confidence	Emergency workflow
IP opportunity	Stability and packaging	Device plus formulation	Absorption enhancer and device	Nebulizer and aerosol formulation
Generic substitution risk	High	Moderate	Emerging	Product-specific

Standard injectable epinephrine is exposed to significant generic competition because the active ingredient and basic formulation are well established. Autoinjectors retain more defensible commercial value because the device, human-factors package, and combination-product requirements increase development complexity.

Nasal epinephrine has greater formulation differentiation but also greater clinical and regulatory risk. Its commercial position depends on proving that delivery is fast, reliable, and usable in real-world anaphylaxis conditions.

What patents protect epinephrine formulations and delivery systems?

The epinephrine molecule itself is long off patent. Commercial protection has shifted to formulation, device, delivery route, manufacturing, and method-of-use claims.

Formulation patent categories

Relevant patent claim types include:

• Antioxidant-free or low-antioxidant epinephrine compositions.
• Specific pH and buffer ranges.
• Surfactant-enhanced nasal compositions.
• Chelator-containing formulations.
• Preservative-free multidose or unit-dose products.
• Stable aqueous compositions with defined impurity limits.
• Oxygen-controlled filling processes.
• Container closure systems.
• Freeze-dried or reconstitutable epinephrine.
• Compositions that remain stable after temperature excursions.

Device and combination-product claims

Autoinjector and nasal-spray patents may cover:

• Dose delivery mechanisms.
• Needle deployment.
• Automatic needle retraction.
• Cartridge geometry.
• Nasal actuator design.
• Plume angle and droplet size.
• Two-dose or repeat-dose configurations.
• Misfire prevention.
• End-of-life indicators.
• Human-factors features.

For a follow-on sponsor, freedom-to-operate analysis must cover both drug patents and device patents. A formulation that avoids a composition patent can still infringe a device claim if it uses a protected actuator or cartridge architecture.

What is the FDA regulatory status of Adrenalin and epinephrine products?

Adrenalin injection is an FDA-approved epinephrine product. Multiple generic epinephrine injections are also approved. The FDA has approved epinephrine autoinjectors, prefilled systems, and, in 2024, a nasal epinephrine product.[1][2]

Regulatory pathway	Likely use
ANDA under Section 505(j)	Injectable generic with pharmaceutical equivalence to a listed reference product
505(b)(2) NDA	New route, new formulation, new device, or reliance on reference-product data
Full 505(b)(1) NDA	Substantial new clinical and nonclinical development
Combination-product review	Autoinjector, prefilled syringe, nasal spray, or other delivery device
Device-led pathway	Limited applicability because the drug formulation remains central to approval

A nasal product with a novel absorption enhancer generally has a stronger basis for 505(b)(2) development than an injectable product with a minor excipient change. The regulatory submission must address local tolerability, pharmacokinetics, dose proportionality, device performance, and clinical effectiveness.

When does epinephrine lose exclusivity?

Epinephrine has no meaningful molecule-level exclusivity remaining. Generic injectable competition is established, and the principal exclusivity questions concern specific products, devices, formulations, and routes.

Exclusivity and launch timing

Potential launch barriers include:

• Unexpired formulation patents.
• Device patents.
• Method-of-use patents.
• FDA regulatory exclusivity for a new route or formulation.
• Pediatric exclusivity.
• Orange Book-listed patents.
• Patent litigation triggered by a Paragraph IV certification.
• Manufacturing scale-up and device validation.

A generic injection sponsor may pursue an ANDA, while a nasal or device-based sponsor may require a 505(b)(2) NDA. The launch date depends on the relevant patent certifications, litigation stay, settlement terms, regulatory exclusivity, and commercial readiness.

Paragraph IV risk

Paragraph IV challenges are most relevant to branded epinephrine products with Orange Book-listed patents. A generic applicant can certify that a listed patent is invalid, unenforceable, or not infringed. The patent holder may then file litigation, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework.

For epinephrine, the most likely Paragraph IV targets are:

• Nasal absorption-enhancer patents.
• Device patents listed in connection with drug-device products.
• Stable formulation patents.
• Method-of-use patents covering emergency treatment of allergic reactions.

Injectable products with simple, mature formulations face less patent risk but greater price competition.

What manufacturing and IP barriers affect epinephrine products?

Manufacturing barriers are often more significant than active-ingredient supply. Critical controls include:

• Low-oxygen compounding and filling.
• Precise pH adjustment.
• Control of trace metals.
• Protection from light.
• Sterile filtration or aseptic processing.
• Low-bioburden raw materials.
• Device-component compatibility.
• Consistent nasal spray plume performance.
• Extractables and leachables testing.
• Stability-indicating analytical methods.

For nasal products, the absorption enhancer must be manufactured at consistent purity and particle or solution characteristics. Small changes in surfactant quality can affect viscosity, spray pattern, mucosal exposure, and systemic absorption.

For autoinjectors, the combination-product supply chain is a core barrier. Cartridge suppliers, spring mechanisms, needles, elastomers, and assembly sites must remain synchronized. A sponsor with a robust drug formulation but weak device manufacturing may not achieve reliable commercial supply.

Which companies are competing in the epinephrine market?

The competitive landscape includes branded injection suppliers, generic manufacturers, autoinjector companies, and nasal-delivery developers.

Competitive segment	Representative companies or products
Branded epinephrine injection	Par Pharmaceutical and Adrenalin
Autoinjectors	Viatris and EpiPen; Kaleo and Auvi-Q; Teva and generic epinephrine autoinjectors
Nasal epinephrine	ARS Pharmaceuticals and neffy
Generic injections	Multiple FDA-approved manufacturers
Hospital and emergency suppliers	Large injectable-drug manufacturers and contract manufacturers

The commercial competition is moving from the active ingredient to usability, availability, shelf life, insurance coverage, device reliability, and route differentiation.

What is the revenue opportunity for epinephrine excipient innovation?

Revenue exposure is concentrated in anaphylaxis rescue products, emergency departments, schools, public-access programs, ambulances, military systems, and institutional stockpiles. The largest economic opportunity is a differentiated product that commands a premium while reducing replacement, training, or administration costs.

A commercially attractive excipient platform should meet at least one of these criteria:

• Extends shelf life.
• Reduces sulfite exposure.
• Enables needle-free delivery.
• Improves absorption.
• Reduces nasal variability.
• Supports a lower-cost device.
• Enables room-temperature storage.
• Reduces waste in institutional inventories.
• Improves pediatric usability.
• Creates a defensible 505(b)(2) product profile.

The most defensible strategy combines formulation and device claims. A formulation-only patent may be vulnerable to design-around if the active ingredient, route, and excipient function are established. A formulation, process, package, and device portfolio creates more substantial entry barriers.

Key Takeaways

• Adrenalin is an epinephrine injection product whose core formulation relies on sodium metabisulfite, sodium chloride, hydrochloric acid, and water for injection.[1]
• Epinephrine is oxidation-sensitive, making antioxidant selection, pH, oxygen control, light protection, and packaging central to product performance.
• Sulfite-free and low-sulfite formulations are commercially attractive but require strong stability and impurity-control data.
• Nasal epinephrine is the main route-expansion opportunity. Neffy uses dodecylmaltoside to enhance nasal absorption and was FDA approved in 2024.[2]
• Injectable epinephrine faces high generic competition and limited molecule-level patent protection.
• The strongest remaining IP opportunities are formulation, absorption enhancer, device, packaging, manufacturing, and method-of-use claims.
• Autoinjectors and nasal sprays generally provide greater commercial differentiation than standard ampules or vials.
• A successful product strategy should integrate excipient selection, device engineering, container closure design, human factors, and regulatory pathway planning.

Frequently Asked Questions

Can sodium metabisulfite be removed from Adrenalin?

Yes, a sulfite-free formulation is technically possible, but it must replace the antioxidant and oxygen-control function with another validated stability strategy. The product would require new stability, impurity, packaging, and regulatory data.

Does epinephrine require a preservative?

Not necessarily. Many emergency epinephrine products are supplied as single-dose sterile presentations. Preservative selection depends on dose form, container configuration, intended use, and multidose requirements.

Is dodecylmaltoside protected by patent in nasal epinephrine products?

The excipient itself is a known chemical entity. Patent protection may instead focus on its concentration, combination with epinephrine, nasal delivery conditions, device parameters, or resulting pharmacokinetic profile.

Can a generic company copy the excipients in Adrenalin?

An ANDA applicant may use a formulation that is pharmaceutically equivalent or sufficiently comparable to the reference product, subject to FDA requirements and applicable patent certifications. It does not automatically receive freedom to copy unexpired formulation or device claims.

What is the most valuable excipient opportunity in epinephrine?

The highest-value opportunity is a formulation system that improves stability while enabling a differentiated delivery route, especially a sulfite-reduced nasal product with reliable absorption and strong device usability.

References

1. U.S. Food and Drug Administration. (2023). Adrenalin (epinephrine injection) prescribing information. Par Pharmaceutical, Inc.

2. U.S. Food and Drug Administration. (2024). Neffy (epinephrine nasal spray) prescribing information. ARS Pharmaceuticals, Inc.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/